Jasper Therapeutics Inc [NASDAQ: JSPR] plunged by -$0.05 during the normal trading session on Thursday and reaching a high of $7.19 during the day while it closed the day at $6.77.
Jasper Therapeutics Inc stock has also gained 18.98% of its value over the past 7 days. However, JSPR stock has inclined by 60.05% in the 3 months of the year. Over the past six months meanwhile, it has lost -67.68% and lost -70.74% year-on date.
The market cap for JSPR stock reached $101.70 million, with 15.02 million shares outstanding and 12.59 million shares in the current float. Compared to the average trading volume of 250.50K shares, JSPR reached a trading volume of 336840 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Jasper Therapeutics Inc [JSPR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for JSPR shares is $47.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on JSPR stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Jasper Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 13, 2025. While these analysts kept the previous recommendation, BMO Capital Markets raised their target price to Outperform. The new note on the price target was released on December 06, 2024, representing the official price target for Jasper Therapeutics Inc stock. Previously, the target price had yet another raise to $70, while JMP Securities analysts kept a Mkt Outperform rating on JSPR stock.
The Price to Book ratio for the last quarter was 2.41, with the Price to Cash per share for the same quarter was set at 3.25.
JSPR stock trade performance evaluation
Jasper Therapeutics Inc [JSPR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 18.98. With this latest performance, JSPR shares gained by 14.75% in over the last four-week period, additionally sinking by -67.68% over the last 6 months – not to mention a drop of -68.33% in the past year of trading.
Jasper Therapeutics Inc [JSPR]: An insightful look at the core fundamentals
Return on Equity for this stock declined to -85.84%, with Return on Assets sitting at -85.84%.
Earnings per share (EPS) analysis for Jasper Therapeutics Inc [JSPR] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for JSPR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Jasper Therapeutics Inc go to -4.15%.
Jasper Therapeutics Inc [JSPR]: Institutional Ownership
There are presently around $87.94%, or 89.07% of JSPR stock, in the hands of institutional investors. The top three institutional holders of JSPR stocks are: VELAN CAPITAL INVESTMENT MANAGEMENT LP with ownership of 1.47 million shares, which is approximately 9.8216%. SOLEUS CAPITAL MANAGEMENT, L.P., holding 1.28 million shares of the stock with an approximate value of $$28.97 million in JSPR stocks shares; and SOLEUS CAPITAL MANAGEMENT, L.P., currently with $$24.2 million in JSPR stock with ownership which is approximately 7.1144%.
